These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 32596272)

  • 1. Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers.
    Takeuchi H; Konnai S; Maekawa N; Minato E; Ichikawa Y; Kobayashi A; Okagawa T; Murata S; Ohashi K
    Front Vet Sci; 2020; 7():330. PubMed ID: 32596272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.
    Mezzadra R; Sun C; Jae LT; Gomez-Eerland R; de Vries E; Wu W; Logtenberg MEW; Slagter M; Rozeman EA; Hofland I; Broeks A; Horlings HM; Wessels LFA; Blank CU; Xiao Y; Heck AJR; Borst J; Brummelkamp TR; Schumacher TNM
    Nature; 2017 Sep; 549(7670):106-110. PubMed ID: 28813410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1.
    Chui NN; Cheu JW; Yuen VW; Chiu DK; Goh CC; Lee D; Zhang MS; Ng IO; Wong CC
    Hepatol Commun; 2022 Jan; 6(1):178-193. PubMed ID: 34558800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment.
    Zhang T; Yu H; Dai X; Zhang X
    Front Immunol; 2022; 13():971428. PubMed ID: 35958549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers.
    Gao F; Chen J; Wang J; Li P; Wu S; Wang J; Ji Y
    Biochem Biophys Rep; 2019 Dec; 20():100690. PubMed ID: 31646201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-Expression with Membrane CMTM6/4 on Tumor Epithelium Enhances the Prediction Value of PD-L1 on Anti-PD-1/L1 Therapeutic Efficacy in Gastric Adenocarcinoma.
    Wang Z; Peng Z; Liu Q; Guo Z; Menatola M; Su J; Li T; Ge Q; Wang P; Shen L; Jin R
    Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CMTM6 as a master regulator of PD-L1.
    Yaseen MM; Abuharfeil NM; Darmani H
    Cancer Immunol Immunother; 2022 Oct; 71(10):2325-2340. PubMed ID: 35294592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1-Independent Manner.
    Long Y; Chen R; Yu X; Tong Y; Peng X; Li F; Hu C; Sun J; Gong L
    Cancer Immunol Res; 2023 Feb; 11(2):241-260. PubMed ID: 36484740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.
    Burr ML; Sparbier CE; Chan YC; Williamson JC; Woods K; Beavis PA; Lam EYN; Henderson MA; Bell CC; Stolzenburg S; Gilan O; Bloor S; Noori T; Morgens DW; Bassik MC; Neeson PJ; Behren A; Darcy PK; Dawson SJ; Voskoboinik I; Trapani JA; Cebon J; Lehner PJ; Dawson MA
    Nature; 2017 Sep; 549(7670):101-105. PubMed ID: 28813417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer.
    Xiao M; Hasmim M; Lequeux A; Moer KV; Tan TZ; Gilles C; Hollier BG; Thiery JP; Berchem G; Janji B; Noman MZ
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33803139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer.
    Zhang C; Zhao S; Wang X
    Cancer Cell Int; 2021 Jan; 21(1):78. PubMed ID: 33509216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma.
    Maekawa N; Konnai S; Okagawa T; Nishimori A; Ikebuchi R; Izumi Y; Takagi S; Kagawa Y; Nakajima C; Suzuki Y; Kato Y; Murata S; Ohashi K
    PLoS One; 2016; 11(6):e0157176. PubMed ID: 27276060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CMTM6, a potential immunotherapy target.
    Liang J; Li S; Li W; Rao W; Xu S; Meng H; Zhu F; Zhai D; Cui M; Xu D; Cai J; Zhang B
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):47-56. PubMed ID: 34783871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients.
    Koh YW; Han JH; Haam S; Jung J; Lee HW
    Oncoimmunology; 2019; 8(10):e1629261. PubMed ID: 31646074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors.
    Imamovic D; Vranic S
    Ann Transl Med; 2017 Dec; 5(23):467. PubMed ID: 29285500
    [No Abstract]   [Full Text] [Related]  

  • 16. The clinical and prognostic significance of CMTM6/PD-L1 in oncology.
    Yaseen MM; Abuharfeil NM; Darmani H
    Clin Transl Oncol; 2022 Aug; 24(8):1478-1491. PubMed ID: 35278198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer.
    Tian Y; Sun X; Cheng G; Ji E; Yang S; Feng J; Zheng L
    Ann Transl Med; 2021 Jan; 9(2):131. PubMed ID: 33569433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel extracellular role of REIC/Dkk-3 protein in PD-L1 regulation in cancer cells.
    Gohara Y; Tomonobu N; Kinoshita R; Futami J; Audebert L; Chen Y; Komalasari NLGY; Jiang F; Yoshizawa C; Murata H; Yamamoto KI; Watanabe M; Kumon H; Sakaguchi M
    J Mol Med (Berl); 2023 Apr; 101(4):431-447. PubMed ID: 36869893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody.
    Jia XM; Long YR; Yu XL; Chen RQ; Gong LK; Geng Y
    Acta Pharmacol Sin; 2023 May; 44(5):1095-1104. PubMed ID: 36418428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
    Wu X; Lan X; Hu W; Zhang W; Lai X; Xu S; Li J; Qiu W; Wang W; Xiao J; Wang F; Ding Y; Liang L
    Cancer Immunol Immunother; 2021 Nov; 70(11):3235-3248. PubMed ID: 33818637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.